Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients (PEDISTAD BIOMARKER STUDY)
Completed · NCT03849716
Conditions: Dermatitis Atopic
At a glance
- Research payments reported, 2025
- $1,418
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 266
About the trial
- Sponsor
- Sanofi
- Tested
- Blood sample (other), Cheek swab (other)
- Dates
- Started 2019-04-05; completion 2026-04-20
- Results posted
- Not yet
Primary Objective: To explore associations between biomarkers of atopic dermatitis (AD) and: * Disease state and time course of AD, * Disease state and evolution of selected atopic comorbid conditions, * Effectiveness of specific AD treatments.
From ClinicalTrials.gov, last updated 2026-07-06. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $1,418 in research payments for this study in 2025 (5 payments).
Products named: Dupixent
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Corey L. Hartman, M.D. Dermatology · Birmingham, AL
- Lacey Kruse, MD Dermatology · Chicago, IL
- Neil L. Kao, MD Allergy & Immunology · Greenville, SC
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Northwestern University $774
- Dorisca Research Consulting Llc $325
- Adac Research PA $319
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.